Vaughan & Asbury's General Ophthalmology> 17th Edition
Introduction
In this chapter we will discuss blindness as a worldwide health problem, summarizing information about its epidemiology, emphasizing the value of community-based methods to prevent or treat its causes, and outlining resources available in more developed countries for rehabilitation of the blind. All of the disorders that may cause blindness are discussed more fully in other parts of this book.
Definition of Blindness
The World Health Organization (WHO) defines visual impairment as shown in Table 1. WHO officials encourage investigators and reporting agencies in all countries to report blindness and visual disability according to the categories defined in this table.
| |||||||||||||||||||||||||||||||
|
Visual field
In the United States, the most widely used definition of partial blindness is that used by the Internal Revenue Service for the purpose of determining who is eligible for tax deductions on that basis: central visual acuity 20/200 or less in the better eye with best correction, or widest diameter of visual field subtending an angle of no greater than 20 degrees. An alternative functional definition is loss of vision sufficient to prevent one from being self-supporting in an occupation, making the individual dependent on other persons, agencies, or devices in order to live.
"Industrial blindness" is said to be present when a worker can no longer pursue an occupation because of poor vision; "automobile blindness" when vision is so poor that the responsible licensing agency in that state will not issue a driver's license. The term color blindness is a misnomer since this genetically transmitted disorder is not true blindness as the term is generally understood and implies only a minor visual aberration. Loss of vision may affect only the central fields, only the peripheral fields, or only specific portions of the peripheral fields in one or both eyes. Total loss of vision in one eye is said to reduce visual capacity by only 10%, although it makes the other eye infinitely more valuable.Prevalence of Blindness Throughout the World
WHO estimates that there are more than 50 million blind people in the world today, with at least 135 million suffering significant visual disability. Even where health statistics are most reliable, the methods of counting the blind are often crude and may be applied according to different criteria in different places and at different times within any extensive geographic area. Because of these limitations, extrapolations are often made from small sample studies to large populations. Ninety percent of the world's blind live in developing countries, mostly in Asia (approximately 20 million) and Africa (approximately 6 million), clustered largely in disadvantaged communities in rural areas and urban slums. The risk of blindness in many of these neglected communities is 10–40 times higher than in the industrially developed regions of Europe and
Table 2 lists some countries where fairly reliable data are available about the prevalence of blindness.
1Based on available data, 1969–1980. Some data were only rough estimates when obtained and may have changed markedly since then. In some cases, the survey criteria used did not correspond to WHO definitions. Data taken from Maitchouk IF: Data on blindness: Prevalence and causes throughout the world. In: Lim ASM, Jones BR (editors); World's major blinding conditions. Vision 1982;1:99. (International Agency for the Prevention of Blindness.)Causes of Blindness & Methods of Prevention & Treatment
The relative importance of various causes of blindness differs according to the level of social development in the geographic area being studied. In developing countries, cataract is the leading cause, with trachoma, glaucoma, leprosy, onchocerciasis, and xerophthalmia also being important. Corneal ulceration is also a significant cause of monocular blindness in the developing world. In more developed countries, blindness is to a great extent related to the aging process. Cataract is still important despite the availability of facilities for its treatment, along with age-related macular degeneration and glaucoma. Other causes are diabetic retinopathy, herpes simplex keratitis, retinal detachment, and inherited retinal degenerative disorders.
In terms of the worldwide prevalence of blindness, the vastly greater number of people in the developing world and the greater likelihood of their being affected mean that the causes of blindness in those areas are numerically more important. Cataract is responsible for more than 22 million cases of blindness and glaucoma 6 million, while leprosy and onchocerciasis each blind approximately 1 million individuals worldwide. Interestingly, the number of individuals blind from trachoma has dropped dramatically in the past 10 years from 6 million to 1.3 million, putting it in seventh place on the list of causes of blindness worldwide. Xerophthalmia is estimated to affect 5 million children each year; 500,000 develop active corneal involvement, and half of these go blind. Central corneal ulceration is also a significant cause of monocular blindness worldwide, accounting for an estimated 850,000 cases of corneal blindness every year in the Indian subcontinent alone. As a result, corneal scarring from all causes now is the fourth greatest cause of global blindness.
WHO estimates that up to 80% of blindness in developing countries is avoidable, ie, preventable or treatable. The worldwide eradication of smallpox demonstrates what can be achieved in the area of infectious disease and the superiority of prevention over treatment. Similar efforts are being made to prevent the infectious diseases trachoma, leprosy, and onchocerciasis as well as the noninfectious xerophthalmia. The sheer numbers of individuals blinded by cataract continues to overwhelm the resources available. In all programs to reduce blindness in the developing world, cooperation between governments and nongovernmental charitable organizations has proved to be essential. The WHO Prevention of Blindness Program has established centers in about 60 developing countries to undertake collaborative studies, particularly generating epidemiologically sound information to form the basis for rational planning, implementation, and proper evaluation of programs for prevention of blindness.
In more developed countries, the causes of blindness are less amenable to prevention. In general, it is necessary to rely on recognition and treatment of the early stages of the disease. This depends on education of ophthalmologists, nonophthalmologic medical personnel, and lay people about the necessity for screening for glaucoma and diabetic retinopathy and about the importance of the early symptoms of retinal detachment, age-related macular degeneration, and herpes simplex keratitis. The inherited conditions are amenable to prevention by genetic counseling.
Cataract accounts for at least 50% of cases of blindness worldwide. As life expectancy increases, there is a continuing rise in the total number of people affected. In many parts of the developing world, the facilities available for treating cataract are grossly inadequate, hardly sufficient to cope with the new cases arising and completely inadequate for dealing with the backlog of existing cases, which is conservatively estimated to be 10 million worldwide.
It is not clearly understood why the frequency of cataract in different geographic areas varies so greatly, although exposure to ultraviolet radiation and recurrent episodes of dehydration, such as occur in severe diarrheal diseases, are thought to be important. If medical means could be found to delay the development of cataract by 10 years, it is estimated that this would reduce the number of individuals requiring surgery by 45%. Unfortunately, there is no method of preventing or retarding the growth of cataracts. Although the oral administration of antioxidants was considered promising, clinical studies have now shown conclusively that they have no effect on cataract growth. Mobile eye camps have aided in identifying patients for surgery, but surgery is no longer performed in a camp setting and there are too few well-equipped hospitals and trained surgeons in many developing countries to keep up with the load. In a number of blindness surveys, the problem of uncorrected aphakia is particularly apparent. It is now accepted that intraocular lens implantation at the time of surgery, although requiring greater expertise, is a better solution than relying on the subsequent provision of spectacles.
Trachoma causes bilateral keratoconjunctivitis, generally in childhood, that leads in adulthood to corneal scarring, which, when severe, causes blindness. About 400 million people have trachoma, most of them in Africa, the Middle East, and
Leprosy (Hansen's disease) affects 14 million people in the world and has a higher percentage of ocular involvement than any other systemic disease. Up to 10% of leprosy patients are blind or visually impaired from the disease. The social stigma attached to leprosy has greatly hindered its treatment, but there are now highly effective chemotherapeutic agents that in most cases eradicate the infection. Effective treatment programs using triple drug therapy (dapsone, clofazamine, and rifampin) have markedly reduced the number of cases of leprosy worldwide as well as prevented the deformity and morbidity associated with the disease.
Onchocerciasis is transmitted by bites of the blackfly, which breeds in clear running streams (hence the name river blindness). It is endemic in the greater part of tropical Africa and Central and
The major ophthalmic manifestations of onchocerciasis are keratitis, uveitis, retinochoroiditis, and optic atrophy. The disease is prevented by insect eradication and personal protection by screening. Treatment with ivermectin is extremely effective in killing the microfilaria and sterilizing the adult females residing in nodules in the body. The effect of the mass distribution of ivermectin in areas where onchocerciasis is endemic is a public health success story. Like leprosy, onchocerciasis is definitely decreasing in its importance as a worldwide cause of blindness because of successful treatment programs.
Xerophthalmia is due to hypovitaminosis A. Clinically, there is xerosis of the conjunctiva with characteristic Bitot's spots and softening of the cornea (keratomalacia), which may lead to corneal perforation. Protein malnutrition exacerbates the condition and renders it refractory to treatment. Xerophthalmia is a common cause of blindness in infants, particularly in
Xerophthalmia can be prevented by general dietary improvement or vitamin A supplementation. If the problems of distribution and administration were solved, the cost of a quantity of the vitamin sufficient to prevent blindness in 1000 infants would be only about $25.00. Measles immunization is also important in this regard because of the close association of measles epidemics with the blinding complications of xerophthalmia.
Glaucoma, retinal detachment, diabetic retinopathy, and herpes simplex keratitis are discussed in greater detail elsewhere in this text. The incidence of blindness due to glaucoma has decreased in recent years as a result of earlier detection, improved medical and surgical treatment, and a greater awareness and understanding of the disorder by the lay population. However, in many developing countries, glaucoma is the second most common cause of blindness after cataract. This is especially the case in
Diabetic retinopathy is an increasingly more common cause of blindness everywhere in the world. Recent advances in surgical treatment (vitrectomy, laser therapy) are of some help, but many patients still suffer from proliferative retinopathy, recurrent vitreous hemorrhages, and eventual bilateral blindness. A vast research effort directed at all aspects of diabetes is in progress, and there is justification for hoping that the next generation of diabetics will benefit greatly from what is being done now.
Hereditary conditions are important causes of blindness but should gradually decrease in incidence in response to the efforts of genetic counselors to increase public awareness of the preventable nature of these disorders.
As is true also in other countries where medical care and social services are widely available, blindness in the United States is to a great extent related to the aging process, and about half of the legally blind people in this country are over age 65. The leading causes of blindness in this age group are degenerative retinal disorders, glaucoma, diabetes, and vascular diseases.Costs of Avoiding Blindness
Some examples of what can be achieved for modest outlays of scarce funds are as follows:
1. To cure one person of trachoma in
2. To restore vision to one person in
3. To prevent blindness due to xerophthalmia in one infant in
Rehabilitation of the Blind
Although no completely reliable statistics are available, the most widely used estimates place the legally blind population of the United States at 2.24 per thousand (ie, approximately 500,000). Approximately 50,000 become legally blind annually, and many others have enough visual loss to constitute a serious employment problem.
Blindness does not necessarily imply helplessness. Individual adjustment to marked visual impairment or total blindness varies with age at onset, temperament, education, economic resources, and many other factors. The older patient, for example, may accept blindness quite stoically, whereas for the younger patient, the vocational or social impact of blindness is often catastrophic. Blindness is accepted more easily by persons who are born blind and by persons of any age who lose their vision gradually rather than suddenly.
The aim of rehabilitation is to enable the patient to lead as nearly normal a life as possible. Approximately 5000 blind persons in the
Rehabilitation must be individualized. Many special services (see Appendix III) and increasingly complex optical and nonoptical aids are available, but they are not universally helpful. Different categories of the blind have different needs, and some blind people simply cannot benefit from a number of services or aids available. It has been said that over half of the blind people in the
The responsibility of the physician clearly does not end with the diagnosis, prevention, and treatment of ocular disorders that might result in blindness. The physician caring for the patient who is suddenly faced with actual or imminent blindness is in a position to be of great assistance. When blindness is a possibility but is not inevitable (eg, during acute ocular inflammation), optimism and reassurance are warranted. However, it is unwise to offer false hope or to delay "breaking the news" when blindness is inevitable. If it is certain that blindness will occur, it is important to extend to the distraught patient as well as to the patient's family the warmth, understanding, encouragement, and assistance so desperately needed. The physician should be alert to the severe depressive reactions that may occur.
It is especially important to assist the patient in making the adjustment to blindness while some vision is still present. Early referral to rehabilitation agencies is essential for recently blinded adults and those with irreversible progressive visual loss. Training programs or reeducation for the many changes involved in daily living and employment are greatly simplified if the patient has the partial support provided by even limited vision.
The physician should work actively with both the patient and the family and with other professional people concerned with rendering services to the blind. The physician must know what referral sources are available and how to use them skillfully. Medical social workers, public health nurses, and counseling services and agencies serving the blind and visually handicapped are common sources of reliable information. It may be valuable to have the patient talk with a blind person who has made a satisfactory adjustment to blindness.
Mobility Training & Guide Dogs
Mobility training is most important in rehabilitation of the blind. Many state commissions for the blind offer a wide variety of mobility training courses, either directly or in cooperation with private agencies. The courses are offered on an outpatient and residential basis and have varied objectives according to the special needs of the people who apply for help. The curriculum commonly includes self-care, home functions, and mobility within the community. Several universities1 have undergraduate and postgraduate programs in mobility training for the blind.
The usefulness of guide dogs is limited by their daily care needs and the physical strength required to hold them in check. They are most useful for students and professional men and women in good health who lead fairly well-organized lives. At this time, less than 2% of blind people in the
1Undergraduate-level programs are offered at
This remarkably effective system of reading for the blind was introduced in 1825. The braille characters consist of raised dots arranged in two columns of three. The system is so simple that a blind child can quickly learn to read braille, and proficient readers can learn to read braille as fast as they can talk. The system has been adapted to musical notation and technical and scientific uses also. An international braille code was introduced in 1951.
Braille is used less commonly now than formerly, since many blind people prefer auditory aids both for informational and recreational purposes. But the recent availability of portable data storage systems with braille-encoded input and conventional or braille form printed output has brought about a resurgence of interest. Braille continues to be essential on tags attached to items in common personal use even for people who do not wish to use it for reading.
All paper money in the
Financial Assistance Programs
It is unfortunate that over half of the blind people in the
REFERENCES
Abraham AG et al: The new epidemiology of cataract. Ophthalmol Clin North Am 2006;19:415. [PMID: 17067897] |
Burton MJ et al: Azithromycin for the treatment and control of trachoma. Expert Opin Pharmacother 2002;3:113. [PMID: 11829725] |
Casserley C: Disability, sight impairment, and the law. Br J Ophthalmol 2006;90:1220. [PMID: 16980642] |
Christian P: Recommendations for indicators: Night blindness during pregnancy—a simple tool to assess vitamin A deficiency in a population. J Nutr 2002;132:284S. [PMID: 12221265] |
Dandona L et al: What is the global burden of visual impairment? BMC Med 2006;4:6. [PMID: 16539747] |
Ezz al Arab G et al: The burden of trachoma in the rural Nile Delta of Egypt: A survey of Menofiya governorate. Br J Ophthalmol 2001;85:1406. [PMID: 11734509] |
Fielder AR et al: The management of visual impairment in childhood. Clin Develop Med 1993;128:1. |
Foster A et al: The impact of Vision 2020 on global blindness. Eye 2005;19:1133. [PMID: 16304595] |
Gritz D et al: The antioxidants in prevention of cataracts (APC) study: Effects of antioxidant supplements on cataract progression in |
Harper K et al: Low vision service models in |
Hatt S et al: Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev 2006;4:CD006129. [PMID: 17054274] |
Ho VH et al: Social economic development in the prevention of global blindness. Br J Ophthalmol 2001;85:653. [PMID: 11371481] |
Hogeweg M et al: Prevention of blindness in leprosy and the role of the Vision 2020 Programme. Eye 2005;19:1099. [PMID: 16304590] |
Kestelyn PG et al: HIV/AIDS and blindness. Bull World Health Organ 2001;79:208. [PMID: 11285664] |
Lapointe ML: Services available to sight-impaired and legally blind patients in |
Lewallen S et al: Blindness in |
Pararajasegaram R: The challenge of escalating avoidable blindness: A call for action. Natl Med J India 2001;13:324. [PMID: 11894361] |
|
Resnikoff S et al: Blindness prevention programmes: Past, present, and future. Bull World Health Organ 2001;79:222. [PMID: 11285666] |
Resnikoff S et al: Global data on visual impairment in the year 2002. Bull World Health Org 2004;82:844. [PMID: 15640920] |
Riaz Y et al: Surgical interventions for age-related cataract. Cochrane Database Syst Rev 2006;18:4. [PMID: 17054134] |
Singer MS et al: Recent advances in the global effort to eradicate trachoma. Int Ophthalmol Clin 2006;46:79. [PMID: 16770156] |
Spivey B: The opportunity for international ophthalmology in treating blindness. Trans Am Ophthalmol Soc 2001;99:73. [PMID: 11797322] |
Taylor HR et al: World blindness in a 21st century perspective. Br J Ophthalmol 2001;85:261. [PMID: 11222327] |
Thylefors B et al: Towards the elimination of onchocerciasis. Ann Trop Med Parasitol 2006;100:733. [PMID: 17227651] |
Vitale S et al: Prevalence of visual impairment in the |
West KP Jr: Vitamin A deficiency disorders in children and women. Food Nutr Bull 2003;24:S78. [PMID: 17016949] |
West S et al: Prevention of blindness and priorities for the future. Bull World Health Organ 2001;79:244. [PMID: 11285670] |
Whitcher JP et al: Corneal blindness: A global perspective. Bull World Health Organ 2001;79:214. [PMID: 11285665] |
Whitcher JP et al: Prevention of corneal ulceration in the developing world. Int Ophthalmol Clin 2002;42:71. [PMID: 12189616] |
Wong TY et al: The epidemiology of age related eye diseases in |
I started on COPD Herbal treatment from Ultimate Health Home, the treatment worked incredibly for my lungs condition. I used the herbal treatment for almost 4 months, it reversed my COPD. My severe shortness of breath, dry cough, chest tightness gradually disappeared. Reach Ultimate Health Home via their email at ultimatehealthhome@gmail.com . I can breath much better and It feels comfortable!
ReplyDelete
ReplyDeleteI was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
liver already present. I started on antiviral medications which
reduced the viral load initially. After a couple of years the virus
became resistant. I started on HEPATITIS B Herbal treatment from
ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
treatment totally reversed the virus. I did another blood test after
the 6 months long treatment and tested negative to the virus. Amazing
treatment! This treatment is a breakthrough for all HBV carriers.